Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients
|
|
- Jordan Marshall Manning
- 5 years ago
- Views:
Transcription
1 American Journal of Transplantation 2013; 13: Wiley Periodicals Inc. Continuing Medical Education C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: /ajt Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients R. A. Zuckerman a,b, and A. P. Limaye c a Department of Medicine, Section of Infectious Disease and International Health, Dartmouth-Hitchcock Medical Center, Lebanon, NH b Geisel School of Medicine at Dartmouth, Hanover, NH c Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington Corresponding author: Ajit P. Limaye, limaye@u.washington.edu Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human a -herpesviruses that establish life-long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if no prophylaxis is used, some of them life and organ threatening. While there are effective vaccines to prevent VZV primary infection and reactivation in immunocompetent adults, these vaccines are contraindicated after SOT because they are live-virus vaccines. For HSV, prevention has focused primarily on antiviral strategies because the immunologic correlates of protection and control are different from VZV, making vaccine development more challenging. Current antiviral therapy remains effective for the majority of clinical VZV and HSV infections. Key words: Herpes simplex, prevention, transplantation, treatment, varicella Abbreviations: ACV, acyclovir; CMI, cell-mediated immunity; CMV, cytomegalovirus; DFA, direct fluorescent antibody; FCV, famciclovir; FDA, Food and Drug Administration; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; HZ, herpes zoster; IVIG, intravenous immunoglobulin; PCR, polymerase chain reaction; PHN, postherpetic neuralgia; SOT, solid organ transplant; TK, thymidine kinase; VACV, valacyclovir; VZV, varicella zoster virus. Received 21 June 2012, revised 06 September 2012 and accepted for publication 07 September 2012 Introduction Human herpesviruses (HHV) are ubiquitous human pathogens. Varicella zoster virus (VZV or HHV-3) and the two herpes simplex viruses (HSV-1/HHV-1 and HSV-2/HHV- 1) are the three pathogenic human a-herpesviruses and are characterized by transmission via mucoepithelial contact and establishing latency in neurons. When the human host is initially infected with these viruses (primary infection) there is a wide spectrum of clinical disease, but with immune control of the virus they eventually establish latency. Since VZV and HSV are highly genetically conserved across populations the broad clinical spectrum likely is a function of viral inoculum and host immune characteristics rather than strain differences. These may include host genetic and exogenous immunomodulatory factors (1). Advances in the immunobiologics of solid organ transplantation have improved organ and patient survival but the targets of many of these agents are also important in the immune control of HHV infections. Consequently, continued vigilance in the evaluation of HHV infections in transplant patients is necessary. Clinical Manifestations and Epidemiology (Table 1) Primary infection VZV: Clinically, primary varicella presents as a disseminated pruritic rash that often starts on the face and spreads down the trunk, with relative sparing of the hands and soles of the feet; mucosal involvement can occur. New lesions continue to appear for several days such that patients have lesions of various ages (papules, vesicles and crusted lesions) at the same time. Highly immunosuppressed patients may have more severe primary infection with rapid progression and multiorgan involvement. Prior to the introduction of the varicella vaccine in the United States in 1995, over 90% of the population acquired the disease in childhood (2). Since then, a majority of US children and young adults have been vaccinated with the live Oka virus vaccine, which provides 88 98% protection against all forms of varicella (2). Thus, only approximately 2 4% of adult SOT recipients are seronegative for VZV and therefore susceptible to primary infection (3). HSV: For HSV, a minority of immunocompetent persons develop symptomatic lesions with primary infection. However, in those who do have symptoms, HSV appears as classic vesicular and/or ulcerative lesions and may extend locally in the orolabial, genital or perianal regions (4,5). HSV seronegative SOT recipients may acquire primary HSV from intimate contacts. Rarely, primary HSV infection can be associated with more severe and disseminated disease, including skin, liver, CNS and other organs and 55
2 Zuckerman and Limaye Table 1: Clinical, epidemiology and risk factors for VZV and HSV infections in SOT patients VZV Primary Disseminated pruritic rash, >98% symptomatic starts on face and spreads to trunk, spares hands and feet, lesions in various stages, more severe in immunocompromised. Rarely can causes end-organ damage (liver, CNS, lung, visceral) Reactivated Localized shingles: 2 unilateral dermatomes Disseminated: >2 dermatomes, or 2 noncontiguous, may be atypical or severe/disseminated in SOT patients, cranial nerve/ophthalmic involvement, PHN or superinfection as complications HSV Primary Reactivated Clinical Epidemiology Risk factors Vesicular and/or ulcerative lesions may extend locally in the orolabial, genital or perianal regions. More severe and prolonged in SOT. Dissemination rare (skin, liver, CNS) Asymptomatic reactivation common. Lesions similar to primary infection. Disseminated disease rare >90% VZV exposed in prevaccine era, vaccine 88 98% effective for prevention, 2 4% of SOT recipients are seronegative Incidence consistent for years after transplant (Figure 1) Lung>heart>kidney>liver PHN in 20 40% Prevalence HSV-1: 44% by age 19, 80% by 60 HSV-2: 1.6% by 19, 26.3% by 49. Infection from allograft rare. Acquisition after transplant uncommon 35 68% incidence without prophylaxis Seronegative inhalation or direct contact. Allograft transmission rare Decreased VZV-CMI, older age African American, more immunosuppression, MMF Contact with symptomatic or asymptomatic (shedding). Allograft transmission rare More immunosuppression, ALA and MMF HSV = herpes simplex virus; VZV = varicella zoster virus; SOT = solid organ transplant; PHN = postherpetic neuralgia; CMI = cell-mediated immunity; CNS = central nervous system; MMF = mycofenolate mofetil; ALA = antilymphocyte antibody. See the text for references. is significantly more common in transplant and other immunocompromised persons. Primary infection from the allograft is rare but has been described in liver and kidney transplant recipients, as well as in other organ types (6 9). The presentation is often fulminant with hepatitis and poor outcome. HSV-1 infection, the classic oro-labial virus, has a peak incidence from early childhood through adulthood, with prevalence in the United States of 44% in 12 to 19 year olds and approximately 80% by the age of 60 (10). Because it is primarily sexually transmitted, HSV-2 seroprevalence increases rapidly at the age of onset of sexual activity and then progressively increases thereafter, infecting 1.6% of persons aged years and 26.3% of persons aged years in the United States (11). HSV-1 is an increasing cause of genital lesions, though typically with less frequent recurrences (12,13). Thus, most transplant patients are latently infected with HSV-1 or HSV-2, or both, and are at therefore at risk for reactivated infection. Reactivated infection VZV: VZV, like other HHV, remains latent lifelong in trigeminal and dorsal root ganglia, and is generally symptomatic when reactivation occurs. The most common manifestation of VZV reactivation is cutaneous Herpes Zoster (HZ), or shingles (14). HZ most often presents as a painful vesicular rash that involves 2 adjacent unilateral dermatomes. Herpes zoster occurs at a relatively consistent incidence for years after transplant (Figure 1) (15). In reported cohorts, lung recipients appear to be at highest risk (55.1 cases per 1000 person-years of follow-up) compared with heart (40.0), kidney (24.4) and liver (18.3) (15,16). This is significantly higher than the incidence of 3.6 per 1000 person years in the general population (17). With the advent of primary immunization for varicella, HZ incidence has declined in the general population (18). It remains to be determined if there will be a similar effect on the incidence of HZ in SOT recipients. Secondary complications of HZ include bacterial superinfection and postherpetic neuralgia (PHN), or chronic neuropathic pain at the site of the skin lesions (14). Approximately 20 40% of transplant recipients with HZ will develop PHN, significantly greater than the rate in the general population (16). Disseminated VZV is defined by a distribution of greater than two dermatomes, or involvement of two noncontiguous deromatomes and lesions that may mimic primary 56 American Journal of Transplantation 2013; 13: 55 66
3 VZV and HSV in Solid Organ Transplantation Risk factors (Table 1) VZV primary infection: Varicella zoster virus is highly infectious to seronegative persons and is primarily transmitted through respiratory droplets but can also be spread through direct contact with active skin lesions (14,28,29). Rarely, virus may be aerosolized from patients with active skin lesions and transmitted to mucosal surfaces. Only one donor-transmitted infection has been reported (30). The efficacy of VariZIG TM in immunoprophylaxis for primary varicella is evidence that varicella-specific antibody likely provides some protection against primary infection, but humoral immunity is not important for protection against VZV reactivation (31). In fact, VZV antibodies have been showntobeelevatedinpatientswithdisseminateddisease, possibly due to stimulus by high levels of virus (32). Figure 1: Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients (15). disease. SOT patients who have altered immune status may have atypical or severe clinical findings (19,20). Rarely, patients may develop invasive complications (CNS, visceral) without skin manifestations (zoster sine herpete) (21). VZV reactivation may also present with ophthalmologic findings, with or without rash (22). Herpes zoster ophthalmicus (HZO) and progressive outer retinal necrosis (PORN) are sight-threatening emergencies that require prompt ophthalmologic evaluation and treatment (22,23). The nasociliary nerve innervates the tip of the nose and the globe, so a vesicular rash on the nose (Hutchinson sign) should prompt consideration of ophthalmic involvement. HSV: Compared with VZV, HSV reactivation is a frequent occurrence (5 25% of days), the majority being asymptomatic (24). Solid organ recipients shed virus frequently and also have more frequent and severe clinical manifestations of HSV (25). Most symptomatic HSV disease occurs early after transplantation and in the setting of antirejection therapy (4,5,8). Clinically evident HSV recurrences are characterized by lesions that are similar to primary infection. These lesions may be mistaken for HZ, particularly if they are on the buttock or atypical location; however, HZ usually covers a larger area of the dermatome than HSV. Additionally, if HZ does recur, then it is usually in a different location from prior recurrences, so recurrent lesions in the same location are more likely to be caused by HSV. Visceral or disseminated disease can occur, including disseminated cutaneous disease, esophagitis, hepatitis, CNS disease and pneumonitis (26,27). Fever, leucopenia and hepatitis are common presenting signs of disseminated disease. Pneumonitis is described in recipients of all organ types, but is most common in heart lung recipients (27). VZV reactivated infection: Patients with previous VZV disease or VZV vaccination are at risk for the development of HZ (33), though vaccinated individual are less likely to develop HZ than those infected naturally (18). Few systematic reviews have been done of risk factors for HZ after transplant; thus, a small number of specific risk factors outside of the traditional major factors of age and decreased VZV- CMI have emerged (15,34). In one review, African American patients have increased rates of HZ compared to other transplant recipients, possibly in part related to more intensive immunosuppression due to higher rates of rejection in African American transplant recipients (15). Heart and lung transplant patients, presumably because of their higher immunosuppression requirements, appear to be at increased risk for HZ compared to other organ transplant recipients (3,15,16). Studies have not been designed or powered to determine the risk of specific immunosuppressive agents or combinations; however, in two studies, mycofenolate mofetil (MMF) has been suggested as a potential risk factor for HZ (35,36). There has been some suggestion that use of the rapamycins with reduced calcineurin inhibitor exposure leads to decreased herpesvirus infections (37,38), but the specific effect on VZV incidence has not been confirmed. When one considers the pathogenesis of HZ reactivation, the loss VZV-cell-mediated immunity (CMI) has been the primary risk factor in the development of disease (31,39,40). Therefore, risk for HZ is traditionally highest when this CMI is diminished, such as in the use of immunosuppressive agents targeting CMI primarily as in the treatment of cell-mediated rejection episodes. One must also consider if boosting VZV-CMI may help to prevent HZ after transplant. To date there has been no study evaluating whether or not immunologic stimulus from a prior shingles episode or the use of pretransplant immunization decreases the risk of posttransplant HZ in SOT patients. HSV primary infection: In comparison with primary VZV that is transmitted through the respiratory route, primary HSV is transmitted through direct contact with infected mucoepithelial surfaces. Since asymptomatic shedding is frequent, HSV is most often acquired from persons without clinical lesions (41). Knowledge of serostatus of the organ transplant candidate is important in determining American Journal of Transplantation 2013; 13:
4 Zuckerman and Limaye Table 2: Laboratory methods for diagnosis of VZV and HSV Test Advantage Disadvantage Direct fluorescent Rapidly available Lower sensitivity than PCR Antibody (DFA) Virus specific Limited sample types (need cells to stain; e.g. not CSF) PCR Most sensitive Not available at all centers Done on most sample types Culture Type specific Takes longer Able to isolate virus for drug susceptibility Less sensitive testing HSV only 25% of PCR positive Depends on level of virus (50) VZV <10% sensitive (52) Tzank smear Rapid Requires experience Direct visualization Nonspecific (HSV or VZV) Histopathology with Can prove tissue-invasive disease Samples more difficult to acquire immunohistochemistry Long turnaround Serology Useful to guide pre-transplant risk stratification and prevention Not useful posttransplant, insensitive marker for acute infection False-positive IgM with HSV reactivation whether the patient is at risk for primary HSV acquisition, either from the allograft or from close contacts after transplant. Primary HSV infection in SOT recipients tends to be clinically severe and prolonged due to lack of immunologic memory (42,43). HSV reactivated infection: HSV seropositive recipients are at risk of clinical reactivation posttransplant in the absence of antiviral prophylaxis even if they have not had prior clinical HSV disease. The incidence of clinically apparent HSV disease in seropositive patients not receiving prophylaxis ranges from 35% to 68% (5,8,44). Because severe HSV disease can occur in seropositive or in seronegative persons who newly acquire the infection, HSV should be considered in the differential diagnosis of clinically appropriate syndromes regardless of serostatus prior to transplant. As with VZV, few studies have assessed the incidence of HSV reactivation with various immune suppression regimens. Historically, antilymphocyte antibodies and mycophenylate mofetil have been associated with increased risk of HSV reactivation after transplantation (8,45,46). The effect of other agents has not been well studied. Diagnosis Clinical findings are a cornerstone for the diagnosis of the majority of VZV and HSV infections, but because of the varied nature of clinical presentation in transplant recipients, supportive diagnostics are important. Similar diagnostic tests are available for the two viruses, and each test has its advantages and disadvantages (Table 2). Rapid diagnostic methods are essential to clinical management and include direct fluorescent assays (DFA) and polymerase chain reaction (PCR) (47,48). DFA is performed on scrapings taken from the base of a lesion or other tissue specimen, and is a rapid and reliable method for diagnosing VZV and HSV disease, and for differentiating the two. PCR testing is the most sensitive test (49,50), can also be done on blood and other fluids (e.g. spinal, bronchoalveolar lavage, vitreous), but may not be available with rapid turnaround at all centers. HSV grows much better in tissue culture than VZV, and most isolates are identified within 5 days. Shell vial culture (a more rapid culture using permissive cells) is more sensitive than tissue culture for VZV, is available within 48 h and is very specific (51); however, culture has historically been less sensitive than PCR (50,52,53). Tissue histopathology can be helpful with immunocytochemistry for HSV and VZV. All transplant recipients should have serology for VZV and HSV prior to transplant to assist in guidance of peritransplant prevention (see below). VZV and HSV seropositive patients are at risk for reactivation disease. Disseminated VZV disease usually occurs as a reactivation disease so most patients are seropositive. Negative serology (including IgM) in the setting of acute primary infection does not rule out primary infection given its lack of sensitivity in the SOT population. As a result, serologic testing is not indicated in the diagnosis of acute clinical HSV and VZV infection, but is important as a screening tool prior to transplant to predict risk posttransplant and to identify patients for whom VZV vaccination is appropriate. HSV and VZV serologic testing are not routinely done in donors because the results will not affect clinical care. Immunity is not transferred and donor serology does not predict the rare case of allograft transmission of either virus. Treatment (see Table 3) Varicella: Primary, disseminated and visceral varicella require the early initiation of intravenous acyclovir 10 mg every 8 h to optimize clinical outcomes (54,55). While some experts support reduction in immunosuppression, there have been no controlled trials of this approach and the overall risk to the patient with regard to the likelihood of organ rejection, adrenal insufficiency and the possibility of allowing for the development of a more robust inflammatory response need to be considered. VZV-specific 58 American Journal of Transplantation 2013; 13: 55 66
5 Table 3: Treatment of VZV and HSV in solid organ transplant patients (81,100) VZV and HSV in Solid Organ Transplantation Clinical disease VZV HSV Comments Localized mucocutaneous ACV 800 mg po 5 /day 400 mg po tid Prompt initiation of therapy is associated VCV 1 g po tid 1 g po bid with improved outcomes FCV 500 mg po tid 500 mg po bid Therapy should be continued until complete crusting (VZV) or healing (HSV) of all lesions Disseminated mucocutaneous or invasive disease, primary varicella visceral, CNS ophthalmic VZV Ramsey Hunt syndrome lesions involving the face Acyclovir resistant disease ACV iv 10 mg/kg q 8 h ACV iv 5 10 mg/kgq8h Foscarnet iv mg/kg/day in 2 3 divided doses Intravenous cidofovir Cutaneous HSV: Topical cidofovir or trifluridine Investigational agents: lipid ester cidfovir, helicase-primase inhibitors IV therapy can be changed to oral therapy once the patient has significantly improved IV therapy should be given for at for at least 7 days, but may need to be given for longer in patients with extensive involvement or CNS disease Ophthalmology consultation is recommended for patients with ophthalmic involvement Acyclovir resistance may be seen in HSV and is rare in VZV Resistance testing is recommended before initiating therapy unless there is strong clinical evidence for lack of response Dosages are for GFR 50, adjustment is necessary for renal insufficiency. HSV = herpes simplex virus; VZV = varicella zoster virus; ACV = acyclovir; VACV = valacyclovir; FCV = famciclovir; SOT = solid organ transplant; po = per orally; iv = intravenously; tid = three times a day; bid = twice daily. immune globulin preparations are difficult to obtain rapidly, are expensive, and have not been systematically studied in the setting of disseminated disease; however, some clinicians have reported the use of nonspecific immunoglobulins (IVIG), the efficacy of which has not been established (56). Herpes zoster: Mild localized cutaneous HZ can be treated with oral acyclovir (800 mg five times a day), valacyclovir (1 g three times a day) or famciclovir (500 mg three times a day) (57). Treatment is given for a minimum of 7 days, and may need to be continued for longer in the compromised host whose lesions may not crust over quickly. Adjunctive therapies to prevent PHN have not been evaluated in SOT patients. Patients with localized disease involving the face (trigeminal and geniculate ganglions) should be considered for IV acyclovir therapy (10 mg/kg every 8 h) given the potential for ocular (herpes zoster ophthalmicus) and facial nerve (Ramsay Hunt syndrome) complications (58). HSV: As with VZV, disseminated, visceral or extensive cutaneous or mucosal HSV disease should be treated with intravenous acyclovir, though the dose is usually lower at 5 10 mg every 8 h (6,26,59 61). Early initiation of acyclovir therapy is associated with improved outcome for HSV disease in transplantation (6), and can be life saving in cases of HSV hepatitis or dissemination. As with VZV, reduction in immunosuppression should be considered for life-threatening HSV disease. More limited mucocutaneous disease can be treated with oral acyclovir, valacyclovir or famciclovir. Therapy should be continued until complete healing of the lesions. Resistance: Resistance to nucleoside analogs occurs more frequently for HSV than VZV. In fact, there are very few clinical reports of acyclovir resistance through thymidine kinase (TK) and DNA polymerase mutations in VZV (62,63) and little therapeutic experience (64). On the other hand, nucleoside analog resistance is found in about 4 7% of immunocompromised patients with HSV (65 67). Very few studies have looked at SOT-specific resistance rates. In a surveillance study for HSV resistance in France, 2.5% or isolates in SOT patients were resistant to ACV (68). In another study in Northwest England, two of 20 (10%) heart or lung transplant recipients in were found to have resistant isolates (69). Thus, resistance rates appear similar in the SOT population to other immunocompromised populations. Acyclovir resistance needs to be considered in patients whose lesions are not responding clinically to appropriate doses of acyclovir therapy. Initial evaluation should include laboratory confirmation of HSV disease and acyclovir susceptibility done on a viral isolate. Foscarnet should be used in patients in whom acyclovir resistance is documented (70). Topical or intravenous cidofovir and topical trifluridine have also been associated with improvement (71). To the extent possible, doses of immunosuppressive therapy should be reduced in patients with acyclovir resistant disease. Recurrent acyclovir-resistant HSV disease may require repeated courses of foscarnet. However, after complete healing, the subsequent recurrences may be again susceptible to acyclovir therapy. Novel American Journal of Transplantation 2013; 13:
6 Zuckerman and Limaye Figure 2: VZV and HSV prevention in solid organ transplant patients. therapies that are being evaluated include a new lipid-ester formulation of cidofovir and a new helicase-primase inhibitor, ASP2151 (72). Prevention (see Figure 2) Posttransplant antiviral therapy for VZV and HSV Antiviral therapy prevents VZV and HSV reactivation in solid organ transplant patients (16,73). When used as universal prophylaxis for cytomegalovirus (CMV) prevention, valgancyclovir, ganciclovir, acyclovir and valacyclovir prevent VZV and HSV reactivation (73). HSV-specific prophylaxis should be considered for all HSV-1 and HSV-2 seropositive organ recipients not receiving antiviral medication for CMV prevention. Therapies used for HSV prevention are generally considered adequate to prevent VZV. In the unusual circumstance of a patient who is not receiving CMV antiviral prophylaxis and is also HSV seronegative, the use of prophylaxis is not specifically recommended, but some clinicians may choose to give antiviral prophylaxis to prevent the rare case of HSV transmission from an organ (6) or to prevent VZV reactivation. However, the risk for VZV reactivation persists for years after transplant (Figure 1) and the relative benefits of extended duration therapy have not been established in this population. Thus, short duration of VZV-specific prophylaxis is not likely to prevent the majority of cases of HZ. Close clinical monitoring with early antiviral therapy at first onset is also an option. This is an area in need of research. Antiviral dosing Early trials of HSV-specific prophylaxis in SOT recipients showed effective HSV suppression with acyclovir administered at low doses given three and four times a day (4,5). Subsequent metaanalysis showed that these regimens were as effective as higher dose regimens used for CMV prophylaxis (73). Higher doses of acyclovir administered less frequently (e.g mg 2 /day) have been shown to be safe and effective in other similarly immunocompromised populations (e.g. hematopoietic stem cell transplant, HIV), and are recommended for SOT recipients due to their safety and ease of administration (61,74,75). Additionally, these regimens have been shown to be effective in preventing VZV reactivation in the same populations. Patients with a history of frequent severe clinical HSV reactivations prior to transplant should be given doses in the higher range. Valacyclovir given once daily was found to 60 American Journal of Transplantation 2013; 13: 55 66
7 VZV and HSV in Solid Organ Transplantation be inferior to twice daily when given for HSV suppression in HIV patients so once daily valacyclovir is generally not recommended in immunocompromised patients (76). Duration of HSV-specific prophylaxis The majority of severe HSV disease occurs within the first month after transplant (5), so prophylaxis should continue for at least a month. For patients receiving CMV antiviral prophylaxis, HSV prevention does not need to be continued after this therapy is completed unless the recipient experiences frequent symptomatic reactivation after prophylaxis is stopped. In patients who experience bothersome clinical recurrences after discontinuation of antiviral therapy, suppressive antiviral therapy should be continued until such time as the level of immunosuppression can be decreased. Of note, suppressive therapy can be safely continued for many years and is associated with less frequent acyclovir resistant HSV than episodic therapy in immunocompromised patients (75), and thus is the preferred approach. If cessation of prophylaxis is unsuccessful, then lifelong suppressive therapy may be necessary. Immunosuppression intensification for organ rejection has been associated with VZV and HSV recurrence. Resumption of prophylaxis during rejection episodes is recommended (45). VZV-Specific Prevention Pretransplant vaccination: Seronegative organ transplant candidates without contraindications should be given live attenuated Oka varicella vaccine (Varivax R,Merck& Co, Inc., USA). Though there are limited data in recipients other than kidney and liver transplant patients, this live vaccine appears to be safe and effective in most patients with organ failure prior to transplant (77 79). Seroconversion after vaccination is reduced in end-stage kidney and liver disease (78,80), so two doses should be given prior to transplantation if practical with a minimum interval of 4 6 weeks in between (81). Patients should be vaccinated at least 2 weeks but preferably greater than 4 weeks prior to transplant. Serology should be done after immunization, with consideration of subsequent doses for patients who do not respond to the initial series (78). Additional research is needed to determine optimal vaccination strategies and immune markers of protection. The first trials evaluating the safety of the pretransplant use of the Oka/Merck shingles vaccine (Zostavax R,Merck & Co., Inc., USA) to prevent and/or attenuate the complications of HZ after transplant are ongoing (NCT , NCT ). Pretransplant patients without contraindications who are eligible for the vaccine based on current recommendations should be considered for the vaccine if given greater than 4 weeks prior to transplant. In the rare event that a patient receives vaccination soon before transplant, antiviral therapy is recommended after transplant as the Oka strain is susceptible to acyclovir. Posttransplant vaccination: Seronegative patients who do not receive and/or respond to vaccination pretransplant are at risk for primary infection after transplant. Varivax has been given to seronegative children after transplant on low levels of immunosuppression with some efficacy and little toxicity (79,82); however because of reports of disseminated disease after immunization and a lack of systematic evaluation of safety and efficacy, it is not generally recommended in adults (83). It is important to ensure all close contacts are protected from acquiring primary VZV and potentially exposing the SOT recipient (see the Infection Control section below). Vaccination with Zostavax has been shown to attenuate the risk and incidence of complications from HZ in immunocompetent individuals (84) but until further research is done, it is currently contraindicated in the immunosuppressed SOT population due to the risk of disseminated disease as it is a live-virus preparation. A heat-inactivated (Merck V212) vaccine has shown some promise in preventing HZ in hematologic autologous transplant (40); however, there are no current trials underway in the solid organ transplant population. Infection control: VZV is highly transmissible, so infection control is an important part of any primary prevention method. In the community setting, close contacts and family members 12 months or older should be vaccinated for VZV if they have never received the vaccine, have no history of varicella or HZ, and have no contraindications to vaccination. Vaccinated individuals are less contagious when they develop varicella and secondary attack rates are much lower (85). The risk of transmission of the Oka vaccine strain to transplant recipients is low compared to the benefit of avoiding the risk of severe VZV disease if an unprotected contact were to expose the SOT recipient to primary varicella. Close contacts of transplant patients who receive live attenuated VZV immunization should keep the vaccination site covered and avoid direct contact with the transplant recipient if lesions develop. Transplant recipients should be isolated from vaccinated contacts who develop a varicella-like rash, particularly those with >50 lesions, as vaccine associated rashes can result in transmission (85). In the hospital, patients with varicella or HZ should be placed on airborne and contact isolation, and VZV susceptible close contacts (e.g. seronegative and/or without history of vaccination or disease) should be immunized as soon as possible if not contraindicated (preferably within 3 days of exposure with possible efficacy as late as 5 days postexposure) or given appropriate VZV prophylaxis (86). Patients should be isolated until at least all lesions are crusted, which can be delayed in immunocompromised patients (86). In addition to postexposure prophylaxis, exposed susceptible patients should remain in airborne and contact precautions from day 10 to 21 after exposure to the index patient, and those who receive VariZIG should American Journal of Transplantation 2013; 13:
8 Zuckerman and Limaye remain in precautions until day 28 (86). Patients with localized zoster lesions should also have them covered as this can potentially decrease transmission risk (87); however, secondary transmission from HZ via airborne route or direct contact remains a concern (88). Postexposure prophylaxis: Seronegative transplant recipients are at risk for developing severe primary varicella infection after exposure and should, after a significant exposure, receive postexposure prophylaxis. In the outpatient environment significant exposure to VZV has been defined as exposure to a household contact or nontransient face-to-face contact indoors. In the hospital significant exposure to VZV is defined as exposure in the same 2- to 4-bed room, face-to-face contact with an infectious staff member or patient, or a visit by a person deemed contagious (86). Though less common, VZV can be acquired by direct contact with a person who has active skin lesions since individual lesions have high titers of viral DNA (89). There are case reports of airborne acquisition of VZV from patients with localized HZ (90). Options for postexposure prophylaxis include passive immunoprophylaxis and/or antiviral therapy. The only currently available VZV-specific immune globulin preparation is VariZIG TM (Cangene Corporation, Winnipeg, Canada). The United States Food and Drug Administration (FDA) requires an investigational new drug application through an expanded access protocol and patient informed consent to give this product. The FDA recently expanded the time after exposure before which VariZIG needs to be administered from96hto10days(91),makingitmorefeasibleforsome centers to acquire the drug in the recommended window. While efficacy is greatest when the drug is given as soon as possible after exposure, there is good evidence for efficacy in preventing and/or attenuating disease if it is given up to 10 days after exposure (91). VariZIG is available through a single US distributor (FFF Enterprises; Temecula, California). Although not studied in clinical trials, nonspecific pooled IVIG has been suggested as an alternate postexposure prophylaxis when VariZIG is not available; combination use of IVIG with antiviral therapy in immunocompromised patients can also be considered (92). The use of antiviral agents as postexposure prophylaxis has not been evaluated in randomized clinical trials in immunocompromised patients, but should be considered as adjunctive therapy in patients receiving immunoprophylaxis or in patients who are unable to receive immunoprophylaxis. The value of acyclovir as postexposure prophylaxis has been demonstrated in a study of immunocompetent children (93) and has been suggested to be effective (in addition to immunoprophylaxis) in a small study of highrisk children which included five kidney transplant recipients (94). Due to the unpredictable absorption and low bioavailability of oral acyclovir, valacyclovir, which has improved bioavailability, may be preferred for prophylaxis. Current recommendations are for patients to receive acyclovir or valacyclovir for a 7-day course of therapy beginning 7 to 10 days after varicella exposure (86). Alternatively, some experts believe that those who are highly immunosuppressed should receive longer antiviral prophylaxis from days3to22afterknownexposureandfromdays3to28 if given immunoprophylaxis since immunoprophylaxis may delay the onset of disease (95). Vaccination is not currently recommended as a part of secondary prevention of VZV in organ transplant recipients. HSV-Specific Prevention Prevention of primary infection: Unfortunately, a vaccine to prevent primary HSV infection has been elusive; therefore current prevention techniques are focused on behavioral and antiviral methods to prevent acquisition of HSV. Seronegative transplant recipients should be counseled regarding the risks of HSV-1 and HSV-2 acquisition. It is important to avoid contact with persons with active lesions as these patients are most infectious. However, persons may acquire HSV from asymptomatic individuals so care should be taken in intimate contact, particularly during periods of most intense immune suppression. Condoms may be effective, but do not completely protect against HSV transmission (96). A majority of persons infected with HSV have never had symptoms, so the virus may be acquired from persons who have never had lesions. Where appropriate, HSV-2 seronegative transplant recipients in new sexual relationships should consider having their partner tested for HSV-2. In serodiscordant couples, daily antiviral therapy taken by the seropositive partner has been shown to prevent HSV-2 transmission to the seronegative partner (41), so this may be considered as an option, but has not been evaluated in the SOT population. There are no controlled studies looking at the efficacy of postexposure prophylaxis to prevent HSV acquisition so it is not routinely recommended. Knowledge Gaps Epidemiology As immunosuppressive agents and regimens change, ongoing epidemiologic research is necessary to determine if specific agents are associated with altered risk for VZV and HSV reactivation. As the population ages, more individuals will be coming to transplant who have been primarily vaccinated for VZV as opposed to having had natural infection. Continued epidemiologic research regarding risks for HZ and the possibility VZV reinfection for those with waning immunity will be necessary. Diagnosis VZV and HSV diagnostics have improved substantially with the advent of PCR. However, not all centers have PCR testing for VZV and HSV readily available for various specimen types. Additionally, the appropriate clinical use of PCR testing needs further clarification. For example, 62 American Journal of Transplantation 2013; 13: 55 66
9 VZV and HSV in Solid Organ Transplantation HSV PCR testing may be positive from typically sterile sites in the setting of other acute illnesses (97). Formative research needs to be done to determine the clinical and epidemiologic significance of these positive tests (98). Treatment Acyclovir remains an extraordinarily safe and effective agent with little resistance in both VZV and HSV. However, the higher IC50 for VZV can make therapy challenging for certain patients. Thus, the pipeline for antiherpes medication development should include mechanisms for early research into drug efficacy for treatment of SOT patients. This would specifically need to include the evaluation of medication levels and interactions with immunosuppressive therapies. The novel helicase-primase inhibitors are not yet being evaluated in SOT patients. The transplant community needs to continue efforts at collaborative multi-center studies to improve access to diverse patient populations. Prevention Primary VZV prevention works when vaccines are given pretransplant, but response rates to the current vaccine preparations are suboptimal and the immune correlates of vaccine response have not been well defined in SOT patients. We still use antibody response as a marker for prior exposure and protection from primary infection with VZV; however, we know that alternative immune responses are necessary for protection and some previously VZV exposed transplant recipients may be seronegative but experience HZ after transplant (34). Further research into improving vaccine response and determining the appropriate markers for protection in the SOT population are necessary. Adjuvant vaccine algorithms should also be evaluated in the SOT population. In contrast to VZV, HSV-specific vaccines have been difficult to develop. This is due to major differences in the immune control of HSV as compared with VZV. VZV vaccination produces robust antibody and CMI responses in immune competent hosts which both prevent primary infection and reactivation. It appears that HSV prevention and control are more complex than for VZV, so both preventive and therapeutic HSV vaccine trials have been disappointing to date (99). While VZV-CMI is the primary driver to prevent reactivation of varicella, control of HSV is a function of complex local and systemic innate and adaptive immune responses. Future HSV vaccine studies will need to incorporate measures of protection that may be altered in the SOT population. As previously noted, further research needs to be done regarding antiviral treatment (used by both recipients and their partners) to prevent primary infection with HSV leading into and after transplant. With >20% of transplant recipients experiencing zoster reactivation during their lifetime, and up to 45% of those developing PHN, it is imperative to do more research to prevent HZ. This should include different vaccine products given both pre and posttransplant and also in the discovery of immune correlates of protection and consideration of modification of regimens to optimize infection prevention. The long-term use of acyclovir is common in the stem cell transplant patient population where lifelong immunosuppression is not the norm as it is in the SOT population. Future research should evaluate immunologic triggers for VZV and HSV reactivation and the limited use of antivirals during periods of highest risk. With current technologies, we should move to identify immune correlates of risk for HHV reactivation so that care may be individualized in the future. Disclosure The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. R.A.Z. has received research grant funding from Astellas Pharma. A.P.L. has received consulting, research support, and/or speaking fees from: Astellas Pharma, Merck, BioRad, Novartis, Genentech and Amgen. References 1. Koelle DM, Bergemann TL. Doctor, why is my herpes so bad? The search continues. J Infect Dis 2008; 197: Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985; 39: Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985; 254: Basse G, Mengelle C, Kamar N, et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection 2008; 36: Dummer JS, Armstrong J, Somers J, et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987; 155: Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: Goodman JL. Possible transmission of herpes simplex virus by organ transplantation. Transplantation 1989; 47: Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, Sex Transm Dis 2004; 31: Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296: American Journal of Transplantation 2013; 13:
10 Zuckerman and Limaye 12. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30: Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30: Gnann JW, Jr., Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis 2011; 13: Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27: Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccinationassociated decreases in the incidence of varicella, J Infect Dis 2005; 191: Oh KH, Ahn C, Kim YS, et al. Atypical generalized zoster with suspicious esophageal involvement and early relapse in an adult renal transplant recepient. Transplant Proc 2002; 34: Volpi A. Severe complications of herpes zoster. Herpes 2007; 14(Suppl 2): Gilden DH, Dueland AN, Devlin ME, Mahalingam R, Cohrs R. Varicella-zoster virus reactivation without rash. J Infect Dis 1992; 166(Suppl 1): S30 S Papanicolaou GA, Meyers BR, Fuchs WS, et al. Infectious ocular complications in orthotopic liver transplant patients. Clin Infect Dis 1997; 24: Ganatra JB, Chandler D, Santos C, Kuppermann B, Margolis TP. Viral causes of the acute retinal necrosis syndrome. Am J Ophthalmol 2000; 129: Wald A, Zeh JE, Selke SA, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342: Greenberg MS, Friedman H, Cohen SG, Oh SH, Laster L, Starr S. A comparative study of herpes simplex infections in renal transplant and leukemic patients. J Infect Dis 1987; 156: Kusne S, Schwartz M, Breinig MK, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163: Smyth RL, Higenbottam TW, Scott JP, et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 1990; 49: Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis 1994; 169: Suzuki K, Yoshikawa T, Tomitaka A, Suzuki K, Matsunaga K, Asano Y. Detection of varicella-zoster virus DNA in throat swabs of patients with herpes zoster and on air purifier filters. J Med Virol 2002; 66: Fall AJ, Aitchison JD, Krause A, Hasan A, Hamilton JR, Gould FK. Donor organ transmission of varicella zoster due to cardiac transplantation. Transplantation 2000; 70: Arvin AM. Humoral and cellular immunity to varicella-zoster virus: An overview. J Infect Dis 2008; 197(Suppl 2): S58 S Gershon AA, Steinberg SP. Antibody responses to varicellazoster virus and the role of antibody in host defense. Am J Med Sci 1981; 282: Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009; 28: Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: Incidence and risk-factor analysis. Transpl Infect Dis 2008; 10: Lauzurica R, Bayes B, Frias C, et al. Disseminated varicella infection in adult renal allograft recipients: Role of mycophenolate mofetil. Transplant Proc 2003; 35: Satoh S, Tada H, Murakami M, et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005; 37: Pliszczynski J, Kahan BD. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Transplant Proc 2011; 43: Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011; 11: Gershon AA, Steinberg SP. Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun 1979; 25: Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350: Corey L, Holmes KK. Genital herpes simplex virus infections: Current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983; 98: Nichols WG, Boeckh M, Carter RA, Wald A, Corey L. Transferred herpes simplex virus immunity after stem-cell transplantation: Clinical implications. J Infect Dis 2003; 187: Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: Tang IY, Maddux MS, Veremis SA, Bauma WD, Pollak R, Mozes MF. Low-dose oral acy lovir for prevention of herpes simplex virus infection during OKT3 therapy. Transplant Proc 1989; 21(Pt 2): Buell C, Koo J. Long-term safety of mycophenolate mofetil and cyclosporine: A review. J Drugs Dermatol 2008; 7: Coffin SE, Hodinka RL. Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J Clin Microbiol 1995; 33: Weinmann S, Chun C, Mullooly JP, et al. Laboratory diagnosis and characteristics of breakthrough varicella in children. J Infect Dis 2008; 197(Suppl 2): S132 S American Journal of Transplantation 2013; 13: 55 66
Recommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman
Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationDisseminated shingles acyclovir
Disseminated shingles acyclovir The Borg System is 100 % Disseminated shingles acyclovir Two developed disseminated herpes zoster, one developed cytomegalovirus. Reduced response to acyclovir,. Disseminated
More informationVARICELLA. Dr Louise Cooley Royal Hobart Hospital
VARICELLA Dr Louise Cooley Royal Hobart Hospital Varicella Zoster Virus (VZV): The Basics Herpes virus Exclusively human infection Primary infection: varicella (chickenpox) Neurotropic, establishing latency
More informationTo provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More informationGENITAL HERPES. 81.1% of HSV-2 infections are asymptomatic or unrecognized. Figure 14 HSV-2 seroprevalence among persons aged years by sex.
GENITAL HERPES Genital herpes is a chronic, lifelong, sexually transmitted disease caused by herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). HSV-1 typically causes small, painful, fluid-filled,
More informationShingles prophylaxis acyclovir
Shingles prophylaxis acyclovir Search 27-2-2018 Detailed Acyclovir dosage information for adults and TEENren. Includes dosages for Herpes Simplex - Suppression, Herpes Simplex Labialis, Herpes Zoster.
More informationProf Dr Najlaa Fawzi
1 Prof Dr Najlaa Fawzi is an acute highly infectious disease, characterized by vesicular rash, mild fever and mild constitutional symptoms. is a local manifestation of reactivation of latent varicella
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationVZV, EBV, and HHV-6-8
VZV, EBV, and HHV-6-8 Anne Gershon Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Ability to cause recurrent infections (reactivation
More informationSummary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies
Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies Genital herpes is one of the most prevalent sexually transmitted diseases, affecting more than one in five sexually active
More informationHuman Herpesviruses. VZV, EBV, and HHV-6-8. The rash of VZV is vesicular. MID 34
VZV, EBV, and HHV-6-8 Anne Gershon Human Herpesviruses Replication (lytic infection) occurs in a cascade Latency occurs when the cascade is interrupted Transcription of viral genome and protein synthesis
More informationAlphaherpesvirinae. Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV)
Alphaherpesvirinae Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV) HERPES SIMPLEX VIRUS First human herpesvirus discovered (1922) Two serotypes recognised HSV-1 & HSV-2 (1962) HSV polymorphism
More informationHerpes Simplex Viruses: Disease Burden. Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012
Herpes Simplex Viruses: Disease Burden Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012 Mucocutaneous HSV Infections Life-Threatening HSV Diseases
More informationHuman Herpes Viruses (HHV) Mazin Barry, MD, FRCPC, FACP, DTM&H Assistant Professor and Consultant Infectious Diseases KSU
Human Herpes Viruses (HHV) Mazin Barry, MD, FRCPC, FACP, DTM&H Assistant Professor and Consultant Infectious Diseases KSU HERPES VIRUS INFECTIONS objectives: ØTo know the clinically important HHVs. ØTo
More informationIt has been estimated that 90% of individuals
Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1
More informationHerpes zoster. Diagnosis, Complications, Treatment, Prevention 서울대학교병원 FM R2 임하연
Herpes zoster Diagnosis, Complications, Treatment, Prevention 2018.04.14 서울대학교병원 FM R2 임하연 1 2 Overview reactivation of lat ent VZV along sensory nerve VZV(varicella-zoster virus) Human herpes virus-3
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationZoster Vaccine for Older Adults
BC Centre for Disease Control IMMUNIZATION FORUM 29 Zoster Vaccine for Older Adults Michael N. Oxman, M.D. Professor of Medicine and Pathology University of California, San Diego VASDHS Staff Physician
More informationReducing the Sexual Transmission of Genital Herpes
CLINICAL GUIDELINE Reducing the Sexual Transmission of Genital Herpes Compiled by Adrian Mindel Introduction People diagnosed with genital herpes usually have many questions and concerns, a key one being
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationVaricella (Chickenpox) and Varicella Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Varicella (Chickenpox) and Varicella Vaccines September 2018 Photographs and images included in this
More informationHerpes zoster vaccine in Korea
Review article CLINICAL EXPERIMENTAL VACCINE RESEARCH Herpes zoster vaccine in Korea Clin Exp Vaccine Res 2013;2:92-96 pissn 2287-3651 eissn 2287-366X Won Suk Choi Division of Infectious Diseases, Department
More informationHerpes simplex virus I and II: a therapeutic approach
Herpes simplex virus I and II: a therapeutic approach Abstract Van der Plas H Division Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town Hardie D Division of Virology,
More informationWell-known for its typical presentation, classic
CASE REPORT Atypical Disseminated Herpes Zoster: Management Guidelines in Immunocompromised Patients Daniel J. Lewis, BA; Megan J. Schlichte, MD; Harry Dao Jr, MD PRACTICE POINTS Clinician awareness of
More informationUC Davis Dermatology Online Journal
UC Davis Dermatology Online Journal Title Disseminated varicella-zoster virus in an immunocompetent adult Permalink https://escholarship.org/uc/item/3cz2x99b Journal Dermatology Online Journal, 21(3) Authors
More informationIntroduction to Viruses That Infect Humans: The DNA Viruses
Chapter 24 Introduction to Viruses That Infect Humans: The DNA Viruses Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 24.1 Viruses in Human Infections and Diseases
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationLRI Children s Hospital. Management of chicken pox exposure in paediatrics
LRI Children s Hospital Management of chicken pox exposure in paediatrics Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team approval date: October 018 Version: V 3 Revision
More informationAntiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiviral Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Viruses Viruses are the smallest infective agents, consisting of nucleic acid (DNA or RNA) enclosed
More informationCOMMON VIRAL INFECTIONS. Dr D. Tenea Department of Dermatology University of Pretoria
COMMON VIRAL INFECTIONS Dr D. Tenea Department of Dermatology University of Pretoria GENERAL Viral infections of the skin important in immunocompromised Pts. Infection: direct inoculation ( warts ) or
More informationLab 3: Pathogenesis of Virus Infections & Pattern 450 MIC PRACTICAL PART SECTION (30397) MIC AMAL ALGHAMDI 1
Lab 3: Pathogenesis of Virus Infections & Pattern 450 MIC PRACTICAL PART SECTION (30397) 2018 450 MIC AMAL ALGHAMDI 1 Learning Outcomes The pathogenesis of viral infection The viral disease pattern Specific
More informationHuman Herpesviruses. Medical Virology, 27 Nov 2015.
Human Herpesviruses Assoc.Prof. Murat Sayan Kocaeli Üniversitesi, Rutin PCR Lab. Sorumlu Öğt.Üyesi Yakın Doğu Üniversitesi, DESAM Kurucu Öğrt. Üyesi sayanmurat@hotmail.com 0533 6479020 Medical Virology,
More informationWrite an account on laboratory diagnosis and prevention of chickenpox virus?
Write an account on laboratory diagnosis and prevention of chickenpox virus? The clinical presentations of varicella or zoster are so characteristic that laboratory confirmation is rarely required. Laboratory
More informationSafety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs
(2010) 45, 1602 1606 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 www.nature.com/bmt ORIGINAL ARTICLE Safety of the live, attenuated varicella vaccine in pediatric recipients of
More informationShingles: What s New to Know
This material was prepared by the New England Quality Innovation Network-Quality Improvement Organization (NE QIN-QIO), the Medicare Quality Improvement Organization for New England, under contract with
More informationAtlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique
Atlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique Reviewed and approved by specialists at the IWK Health Centre, Halifax,
More informationMedChem401 Herpesviridae. Herpesviridae
MedChem401 Herpesviridae Members of the herpesvirus family have been identified in more than 80 different animal species Eight have been identified as human pathogens Herpes viruses are a leading cause
More informationAntiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiviral Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Viruses Viruses are the smallest infective agents, consisting of nucleic acid (DNA or RNA) enclosed
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More informationVaccination to protect against shingles
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2018 and contraindications and precautions Revised July 2018 NES and HPS accept
More informationFor more information about how to cite these materials visit
Author(s): David Miller, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationAntiviral Agents I. Tutorial 6
Antiviral Agents I Tutorial 6 Viruses, the smallest of pathogens, are unable to conduct metabolic processes on their own, they use the metabolic system of the infected cell to replicate ( intracellular
More informationViruses. Poxviridae. DNA viruses: 6 families. Herpesviridae Adenoviridae. Hepadnaviridae Papovaviridae Parvoviridae
Viruses DNA viruses: 6 families Poxviridae Herpesviridae Adenoviridae Hepadnaviridae Papovaviridae Parvoviridae Human herpesviruses Three subfamilies (genome structure, tissue tropism, cytopathologic effect,
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationHSV DNA replication. Herpesvirus Latency. Latency and Chemotherapy. Human Herpesviruses - subtypes. Acyclovir (acycloguanosine) {Zovirax}
Human Herpesviruses - subtypes Herpes Simplex I (HSVI) - herpes labialis (cold sores) herpes keratitis (eye infections) HSVII - herpes genitalis (genital herpes) Varicella Zoster virus (VZV) Chicken pox
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Amar PP,, 2014; Volume 3(3): 123-127 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE A REVIEW ON HERPES ZOSTER AMAR PP 1, AJINKYA C 2, TOHID NB 2, ROHIDAS P 2, AVINASH C 2 1. Assistant
More informationApplied Education and Training, (PAAET).
175 Prednisolone can Prevent Post-Herpetic Neuralgia in Post-Kidney Transplant Recipient Mohammad Ahmed Saraya 1, Mariam Abdulrhman Al-Fadhli 2 and Jafar Abdulrida Qasem 3 1 Department of Tropical Medicine,
More informationPersistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults
MAJOR ARTICLE Persistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults Krow Ampofo, 1 Lisa Saiman, 1,2 Philip LaRussa, 1 Sharon Steinberg, 1 Paula Annunziato, 1 and Anne Gershon 1
More informationThe varicella-zoster virus (VZV) is a
Herpes Zoster Overview: Natural History and Incidence Bethany A. Weaver, DO, MPH The varicella-zoster virus (VZV) causes two diseases. The primary VZV infection, known as chickenpox, typically occurs during
More information9/12/2018. Zoster. Herpes Zoster (Shingles) Complications of Herpes Zoster
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Zoster September 2018 Chapter 22 Photographs and images included in this presentation are licensed solely
More informationEmerging Issues in Reactivated Herpes Zoster Disease
Emerging Issues in Reactivated Herpes Zoster Disease Tim Hilderman, MD FRCPC 2018 Infection Prevention and Control Across the Continuum Friday, June 22 nd, 2018 DISCLOSURE STATEMENT Type of relationship
More informationImpact of Varicella Vaccine on Varicella-Zoster Virus Dynamics
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2010, p. 202 217 Vol. 23, No. 1 0893-8512/10/$12.00 doi:10.1128/cmr.00031-09 Impact of Varicella Vaccine on Varicella-Zoster Virus Dynamics D. Scott Schmid 1 * and Aisha
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors
2017 CST-Astellas Canadian Transplant Fellows Symposium Optimizing use of organs from Increased Risk Donors Atual Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto.
More information- They come in all sizes. -- General Structure is similar.
- They come in all sizes. -- General Structure is similar. Centers for Disease Control (CDC) and Prevention. Influenza Prevention and Control. Influenza. Available at: http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm.
More informationCMV in kidney Transplant recipient: A diagnostic and therapeutic Dilema
CMV in kidney Transplant recipient: A diagnostic and therapeutic Dilema By Mohamed A. Sobh MD,FACP Professor and head of Nephrology Urology and Nephrology Center Mansoura - Egypt Cytomegalovirus Virology
More informationHerpes viruses. Dr.farah hazem. Classification:
Dr.farah hazem Herpes viruses Herpesviridae are a large family of viruses contains several of the most important human viral pathogens. Clinically, the herpesviruses exhibit a spectrum of diseases. Some
More informationHerpes Zoster Ophtalmicus in a HIV positive patient: A Case Report
ISPUB.COM The Internet Journal of Neurology Volume 9 Number 2 Herpes Zoster Ophtalmicus in a HIV positive patient: A Case Report G Lopez Bejerano, Y Graza Fernandez Citation G Lopez Bejerano, Y Graza Fernandez..
More informationThe chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:
Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram
More informationHuman Herpesviruses. Varicella-zoster virus. Human Herpesvirus (VZV) phospholipid envelope, tegument, icosahedral capsid, DNA core
Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Ability to cause recurrent infections (reactivation of latent virus), reinfections
More informationHerpesviruses: The Tired, the Rashy, and the Ubiquitous
Herpesviruses: The Tired, the Rashy, and the Ubiquitous M. Anthony Moody, MD Associate Professor Pediatric Infectious Diseases Chief Medical Officer Duke Human Vaccine Institute Duke University Medical
More informationHerpes zoster results from reactivation
Herpes Zoster Pathogenesis and Cell-Mediated Immunity and Immunosenescence Michael N. Oxman, MD Herpes zoster, or shingles, is a localized disease characterized by unilateral radicular pain and a vesicular
More informationDisclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)
Disclosures I have financial relationships with the following companies: CMV and EBV Infection in Pediatric Transplantation Elekta Inc Lucence Diagnostics Spouse employed Spouse employed I will not discuss
More informationCLINICAL GUIDELINES. Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P.
CLINICAL GUIDELINES Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P. 11/2/15 Several practices routinely delay steroid injections
More informationDarren J. Guffey, MD; Sarah B. Koch, MD, MBA; Leonora Bomar, MD; William W. Huang, MD, MPH
PEDIATRIC DERMATOLOGY Herpes Zoster Following Varicella Vaccination in Children Darren J. Guffey, MD; Sarah B. Koch, MD, MBA; Leonora Bomar, MD; William W. Huang, MD, MPH PRACTICE POINTS Most children
More informationCase 1. Case 1. Physical exam
11/13/2012 Case 28 year-old woman Complains of very painful lesions in vulvar area Increasing severity since 4 days Pain aggravated by urination She has a slight fever and also complains of headache and
More informationCommon Features of Herpesviruses
Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Ability to cause recurrent infections (reactivation of latent virus), reinfections
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationSteps in viral replication (I)
Antiviral agents Steps in viral replication (I) Recognition of the target cell Attachment Penetration Uncoating Macromolecular synthesis Assembly of virus Buddding of enveloped viruses Release of virus
More informationHuman Herpesviruses. Varicella-zoster virus. Human Herpesvirus (VZV) phospholipid envelope, tegument, icosahedral capsid, DNA core
Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Human Herpesvirus (VZV) phospholipid envelope, tegument, icosahedral capsid, DNA core
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Update on Adult Immunization Strategies: Understanding the Current Recommendations EDWARD A. DOMINGUEZ, MD, FACP, FIDSA Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical Center,
More informationSusceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, A
AAC Accepts, published online ahead of print on 23 April 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.00133-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Susceptibility
More informationLes 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies
Les 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies VZV Epidemiology and Pathogenesis 98% adults Respiratory spread 1,000,000/year and increasing CMI continuously boosted
More informationVaricella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis
r 2008 Wiley Periodicals, Inc. Transplant Infectious Disease. ISSN 1398-2273 Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis T. Arness,
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Chickenpox Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Caused
More informationSample Selection- Vignettes
Sample Selection- Vignettes Rangaraj Selvarangan, BVSc, PhD, D(ABMM) Professor, UMKC School of Medicine Director, Microbiology, Virology and Molecular Infectious Diseases Laboratory Director, Laboratory
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Chickenpox Caused
More informationPersistent Infections
Persistent Infections Lecture 17 Biology 3310/4310 Virology Spring 2017 Paralyze resistance with persistence WOODY HAYES Acute vs persistent infections Acute infection - rapid and self-limiting Persistent
More informationZostavax vaccine: now fully subsidised
Dermatology Infections Older person s health Virology Zostavax vaccine: now fully subsidised Zostavax is a herpes zoster (shingles) vaccine that will become fully subsidised from 1 April, 2018 for people
More informationHerpesviruses. -Recurrence: clinically obvious disease due to reactivation. **Reactivation and recurrence are used interchangeably.
*Herpesviruses: A large group of viruses (100 strains), but we are concerned with only 8 strains as they are the only ones to infect human beings *herpesviruses groups: HSV-1 HSV-2 VZV CMV EBV HHV-6 HHV-7
More informationHERPES ZOSTER This resource is designed to offer pharmacists a concise and accurate tool to support assessing,
PHARMACISTS HELPING PROTECT PATIENTS FOCUS ON HERPES ZOSTER This resource is designed to offer pharmacists a concise and accurate tool to support assessing, recommending, and administering vaccines to
More informationProfessor Adrian Mindel
Causes of genital ulceration viruses and others Professor Adrian Mindel University of Sydney VIM 16 th August 2012 Outline Definition Causes Epidemiology Diagnosis Definition of genital ulcer A defect
More informationHerpes virus co-factors in HIV infection
Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationVARICELLA. Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara
VARICELLA (Chicken pox) Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara Definition : Varicella is a common contagious disease caused
More informationOCCUPATIONAL HEALTH DISEASE SPECIFIC RECOMMENDATIONS
Herpes simplex virus (HSV) Cold sores Genital herpes Herpetic whitlow OCCUPATIONAL HEALTH DISEASE SPECIFIC RECOMMENDATIONS contact with primary or recurrent lesions, infectious saliva or genital secretions
More informationSection 10.5 Varicella
Section 10.5 Varicella Chickenpox Introduction Transmission Signs and Symptoms Complications Diagnosis Treatment Infection Prevention and Control Precautions for Residents with Chickenpox Additional considerations
More informationherpesviruses dsdna, linear, enveloped, nm Large genome, codes for 75 viral proteins 50-70% similarity Cross reactivity between HSV and VZV
Herpesviridae herpesviruses dsdna, linear, enveloped, 180-200 nm Large genome, codes for 75 viral proteins 50-70% similarity Cross reactivity between HSV and VZV HSV-2 virus particle. Note that all herpesviruses
More informationHerpes Simplex Virus Genital
National STD Curriculum PDF created November 1, 2018, 6:22 am Herpes Simplex Virus Genital This is a PDF version of the following document: Disease Type 1: Pathogen-Based Diseases Disease 9: Herpes Simplex
More informationHerpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry
Herpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry I have what?! How to break the news Meet the Herpes Quick virology
More informationAcyclovir for ear infections
Acyclovir for ear infections The Borg System is 100 % Acyclovir for ear infections User feedback about Acyclovir side effects covering chicken pox, fatigue, shingles, hair loss, HSV2, dosage, anemia, ear
More informationHERPES VIRUSES 4/16/2014. Disclosures. Case #1. Learning Objectives NONE
Disclosures HERPES VIRUSES 35 th Annual Advances in Infectious Diseases April 24, 2014 NONE Jennifer Babik, MD, PhD Division of Infectious Diseases University of California, San Francisco Learning Objectives
More informationAcyclovir dose for chicken pox
Buscar... Acyclovir dose for chicken pox Acyclovir (Zovirax) treats infections caused by the herpes viruses including genital herpes, cold sores, shingles and chicken pox. Includes Acyclovir side effects.
More informationIMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine
IMMUNIZATION PROTOCOLS FOR PHARMACISTS VARICELLA Live Virus Vaccine I. ORDER: 1. Screen for contraindications and evidence of immunity (Section VII.K.) 2. Provide a current Vaccine Information Statement
More informationICM VI-09 DEFINITION REFERENCES
TITLE/DESCRIPTION: MANAGEMENT OF SELECTED AIRBORNE AND DROPLET INFECTIOUS DISEASE EXPOSURES IN HEALTHCARE WORKERS INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All
More informationBetter laboratory tests and epidemiological studies have
No. 207, April 2008 This guideline has been reviewed by the Infectious Disease Committee and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. PRINCIPAL
More informationCondition: Herpes Zoster Ophthalmicus (HZO)
Condition: Herpes Zoster Ophthalmicus (HZO) Description: Herpes zoster represents a reactivation of the varicella zoster virus (VZV) which leads to characteristic skin lesions and, in many cases, ocular
More information